Evolent Health Inc SEC Filings

Evolent Health, Inc. reported that its Chief Financial Officer received a special one-time restricted stock unit (RSU) grant. On 01/02/2026, the officer acquired 587,500 RSUs for Class A Common Stock at a price of $0 per unit, recorded as a direct holding. The grant was made as an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual.

The RSUs vest over three years, with 34% scheduled to vest on January 2, 2027 and 33% on each of January 2, 2028 and January 2, 2029, subject to the executive’s continued employment through each vesting date. Upon vesting, each unit converts into one share of Class A Common Stock, aligning the CFO’s compensation more closely with the company’s equity performance.

Evolent Health, Inc. filed an initial insider ownership report for its Chief Financial Officer. The filing shows that, as of the event date of January 2, 2026, the CFO reported beneficial ownership of 0 shares of Class A common stock, held directly. The report also indicates no derivative securities, such as options or warrants, reported as beneficially owned. The form is filed as a single-reporting-person filing and references a Power of Attorney dated December 12, 2025 authorizing execution of the document.

Evolent Health, Inc. filed a Form S-8 to register 587,500 shares of its Class A common stock, $0.01 par value per share. These shares are issuable upon the vesting of restricted stock units granted to Mario Ramos as an inducement for him to accept employment as the company’s Chief Financial Officer, in accordance with Section 303A.08 of the New York Stock Exchange Listed Company Manual.

The awards were approved by the Compensation Committee of the Board of Directors and were granted outside the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan. The filing also describes the company’s standard indemnification and liability protections for directors and officers and lists the exhibits supporting this registration, including the form of the award agreement and legal opinions.

Evolent Health, Inc. reported an initial insider ownership filing for one of its directors. The filing states that as of the event date of December 2, 2025, the reporting person, serving in the role of director, does not beneficially own any shares of Evolent Health common stock or other non-derivative securities. The filing also shows no derivative securities, such as options or warrants, reported as beneficially owned. The document is signed by an attorney-in-fact under a power of attorney dated December 4, 2025, indicating the director’s ownership status is formally recorded as zero at this time.

Evolent Health, Inc. reported that its wholly owned subsidiary, Evolent Health LLC, has completed the transactions under a previously announced Stock Purchase Agreement with Privia Management Company, LLC. The agreement was originally dated September 23, 2025, and the deal was consummated on December 5, 2025. This filing simply confirms the closing of that stock purchase arrangement, indicating that the parties have carried out the terms that were agreed earlier in the year.

Evolent Health, Inc. announced that board member Cheryl Scott retired effective December 1, 2025. In connection with her retirement, the board accelerated the vesting of 21,979 restricted stock units that were previously scheduled to vest around the 2026 annual shareholder meeting.

The board appointed Jill Smith, 67, as a new independent director with a term running until the Company’s 2026 annual meeting. She brings more than 25 years of leadership experience, including chief executive roles at several technology and services companies and multiple public-company directorships.

Evolent also reaffirmed its fourth quarter 2025 outlook, guiding to revenue of approximately $462.0 million to $472.0 million and Adjusted EBITDA of about $30.0 million to $40.0 million, consistent with guidance previously issued in a November 6, 2025 press release.

Evolent Health, Inc. (EVH) reported an insider stock purchase by a director. On 11/18/2025, the director bought 10,000 shares of Class A common stock in an open-market transaction coded "P" at a price of $3.8199 per share. Following this trade, the director beneficially owns 58,821 shares, which include restricted stock units granted under prior awards. The filing is made by a single reporting person in the capacity of director and notes the potential use of a Rule 10b5-1 trading plan checkbox, although no selection detail is provided in this excerpt.

Rubicon Fund II LP and affiliates filed a Schedule 13G on Evolent Health (EVH), reporting beneficial ownership of 5,816,123 shares of Class A Common Stock, or 5.21%, as of November 13, 2025. The holdings are reported through an investment in Puma Growth Holdings, LLC.

The filing lists shared voting and dispositive power over 5,816,123 shares and no sole power. The percentage is based on 111,600,856 shares outstanding as of October 31, 2025, as disclosed by the company. Reporting persons include Rubicon Fund II LP, Rubicon Fund II PF LP, Rubicon Founders OP GP II LP, Rubicon Founders OP GP 2, LLC, Rubicon Founders LLC, and Adam Boehler. Within the group, Rubicon Fund II LP reports 5,032,468.70 shares and Rubicon Fund II PF LP reports 783,654.30 shares.

Evolent Health (EVH): Schedule 13G/A update

Durable Capital Partners LP filed Amendment No. 1 to its Schedule 13G reporting beneficial ownership of 0 shares and 0.0% of Evolent Health’s Class A common stock (CUSIP 30050B101), with the event dated September 30, 2025. The filer notes ownership of five percent or less of the class. The certification states the securities were held in the ordinary course and not for the purpose of changing or influencing control.